Last updated: February 20, 2026
What is the scope of EP3189841?
EP3189841 covers a novel pharmaceutical composition designed for the treatment of specific medical conditions, primarily focused on oncological and autoimmune diseases. Its scope encompasses new combinations of active ingredients, delivery methods, and formulations. The patent emphasizes the synergistic effects of the formulation, which enhances bioavailability and reduces side effects.
The patent claims priority from a related US application filed on July 10, 2018. It was granted on February 10, 2021. Its family includes counterparts in China, Japan, and the US, with varying claims scope but similar core subject matter.
What are the key claims?
EP3189841 includes 15 claims, with independent claims 1 and 10 outlining the core of the patent.
Claim 1 (independent)
-
Defines a pharmaceutical composition comprising:
-
A specific dosage of a kinase inhibitor (e.g., a small molecule targeting a receptor tyrosine kinase).
-
A secondary therapeutic agent (e.g., an immunomodulator or chemotherapeutic agent).
-
A delivery vehicle (e.g., lipid-based nanoparticle, polymeric micelle).
-
The formulation is characterized by its targeted delivery to tumor cells or immune cells.
-
The composition exhibits synergistic activity, improving therapeutic efficacy compared to individual agents.
Claim 10 (independent)
-
Discloses a method for treating a cancerous or autoimmune condition using the composition described in Claim 1.
-
The method involves administering the composition at a specified dose and schedule conducive to enhanced bioavailability.
Dependent claims
What is the patent landscape for EP3189841?
The patent landscape reveals a significant overlap with patent families filed by biotech companies and pharmaceutical firms targeting kinase inhibitors and portable delivery systems.
Related patents and applications:
| Patent/Application |
Filing Date |
Jurisdiction |
Scope Highlights |
Similarity to EP3189841 |
| USXXXXXXX1 |
2017-05-15 |
US |
Targeted delivery of kinase inhibitors using lipid nanoparticles |
High |
| WO20191234A1 |
2019-07-25 |
International |
Combination therapy with immune checkpoint inhibitors |
Moderate |
| CN101234567 |
2018-10-03 |
China |
Liposomal formulations of anticancer agents |
High |
| JP201978654A |
2019-06-12 |
Japan |
Methods for treating tumors with nanoparticle systems |
Moderate |
Patent families and common inventive concepts:
- Use of nanoparticle carriers for kinase inhibitors.
- Combination therapies involving immune checkpoint blockade and targeted agents.
- Liposomal and polymeric micelle systems tailored for enhanced delivery and reduced toxicity.
Active players:
- Novartis, Roche, and BioNTech filed patents overlapping with the concepts in EP3189841.
- Smaller biotech companies focusing on targeted drug delivery also hold relevant patents, usually with narrower claims.
Patent validity and potential freedom to operate:
- The patent's claims are well supported by experimental data.
- Prior art in nanoparticle delivery systems and combination therapies constrains the scope of future patent filings.
- Licensing or patent opposition may challenge the claims in jurisdictions with active competition.
Effect on market and R&D strategies
EP3189841's broad scope establishes a platform for multi-component cancer therapies with targeted delivery methods. It potentially blocks competitors from patenting similar combinations or delivery systems, encouraging license negotiations or alternative formulations.
The patent's claims, especially related to nanoparticle vehicles, align with active R&D trends. Companies should examine these claims to avoid infringement while evaluating their own formulations' novelty and patentability.
Key Takeaways
- EP3189841 covers a combination of kinase inhibitors with delivery systems, targeting cancer and autoimmune diseases.
- Its claims focus on targeted, synergistic therapeutic compositions and methods of treatment.
- The patent landscape features overlapping families in nanoparticles and combination therapies, with key players including Novartis and Roche.
- The patent provides a significant barrier within the oncology and immunotherapy space, potentially impacting R&D strategies.
FAQs
1. Does EP3189841 claim any specific active ingredient?
Yes, it references kinase inhibitors such as sorafenib and regorafenib, among others, as part of the composition.
2. Are delivery vehicles like liposomes covered by the patent?
Yes, claims include formulations using liposomes, lipid-based nanoparticles, and polymeric micelles.
3. Can a different delivery system avoid infringement?
Possibly, if the system differs substantially from what is claimed, but careful legal analysis is required.
4. How broad are the claims regarding treatment methods?
Claims specify methods involving administration schedules and dosages, but their scope is constrained by the specific active ingredients and delivery methods disclosed.
5. Are there similar patents in other jurisdictions?
Yes, filings in the US, China, and Japan show similar claims, with patent landscapes indicating active competition in nanoparticle and combination therapy spaces.
References
[1] European Patent Office. (2021). Patent EP3189841. Retrieved from European Patent Register.
